HIV vaccinology: 2021 update

Jeong Hyun Lee; Shane Crotty

doi:10.1016/j.smim.2021.101470

HIV vaccinology: 2021 update

Semin Immunol. 2021 Jan:51:101470. doi: 10.1016/j.smim.2021.101470. Epub 2021 Jul 14.

Authors

Jeong Hyun Lee¹, Shane Crotty²

Affiliations

¹ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA. Electronic address: jhyunl@lji.org.
² Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA; Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA. Electronic address: shane@lji.org.

Abstract

HIV is a virus that remains a major health concern and results in an infection that has no cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues to be an area of intensive research. In this review, we summarize the most recent HIV vaccine efficacy trials, clinical trials initiated within the last 3 years, and discuss prominent improvements that have been made in prophylactic HIV vaccine designs.

Keywords: Broadly neutralizing antibodies; Human immunodeficiency virus; Review; Vaccine.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Antibodies, Neutralizing
HIV Antibodies / therapeutic use
HIV Infections* / prevention & control
HIV-1*
Humans
Vaccinology

Substances

Antibodies, Neutralizing
HIV Antibodies

Grants and funding

UM1 AI144462/AI/NIAID NIH HHS/United States